Investing.com - Financial Markets Worldwide
⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

London stocks subdued as Brexit fears offset first vaccine approval

Published 12/02/2020, 04:14 PM
Updated 12/02/2020, 04:20 PM
© Reuters.
UK100
-
GFSl
-
FTMC
-

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)
* FTSE 100 flat, FTSE 250 down 0.4%

Dec 2 (Reuters) - London-listed shares were muted on
Wednesday as fears about a no-deal Brexit overshadowed news that
the UK had become the world's first country to approve the
Pfizer-BioNTech COVID-19 vaccine.
The blue-chip FTSE 100 .FTSE was flat and the mid-cap FTSE
250 .FTMC down 0.4% even as the government said the vaccine
would be rolled out from early next week. The FTSE 100 had rallied more than 12% in November, marking
its best month in 31 years, on optimism that a COVID-19 vaccine
would soon be available.
Investor attention this week has squarely been on Brexit
negotiations with only weeks left for Britain's transition
agreement to expire.
A senior British minister said there was still a chance of
no-deal Brexit as talks had snagged on fishing, governance rules
and dispute resolution. In company news, security group G4S GFS.L jumped 7% after
Canada's GardaWorld raised its offer for the British company,
valuing it at 3.68 billion pounds ($4.94 billion).

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.